Cerapedics enrolled the first of 364 patients in an Investigational Device Exemption (IDE) clinical trial evaluating next-gen P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion (TLIF).
The prospective, single-blinded, multi-center, randomized, non-inferiority pivotal study will enroll patients at up to 30 U.S. sites, with follow-up at 6 weeks, 3 months, 12 months and 24 months. Investigators can use any FDA-cleared static PEEK interbody and any FDA-cleared pedicle fixation system delivered in an open or minimally invasive technique.
P-15L graft, a substitute for autologous bone, is based on synthetic small peptide technology and was developed to spur bone growth via cell attraction, attachment and activation.
Source: Cerapedics
Cerapedics enrolled the first of 364 patients in an Investigational Device Exemption (IDE) clinical trial evaluating next-gen P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion (TLIF).
The prospective, single-blinded, multi-center, randomized, non-inferiority pivotal study will enroll patients at up to 30...
Cerapedics enrolled the first of 364 patients in an Investigational Device Exemption (IDE) clinical trial evaluating next-gen P-15L Peptide Enhanced Bone Graft vs. autograft in transforaminal lumbar interbody fusion (TLIF).
The prospective, single-blinded, multi-center, randomized, non-inferiority pivotal study will enroll patients at up to 30 U.S. sites, with follow-up at 6 weeks, 3 months, 12 months and 24 months. Investigators can use any FDA-cleared static PEEK interbody and any FDA-cleared pedicle fixation system delivered in an open or minimally invasive technique.
P-15L graft, a substitute for autologous bone, is based on synthetic small peptide technology and was developed to spur bone growth via cell attraction, attachment and activation.
Source: Cerapedics
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.